Raymond James Trust N.A. raised its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 0.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 54,025 shares of the medical research company’s stock after purchasing an additional 475 shares during the quarter. Raymond James Trust N.A.’s holdings in Amgen were worth $11,199,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Pillar Pacific Capital Management LLC lifted its position in shares of Amgen by 0.5% during the 2nd quarter. Pillar Pacific Capital Management LLC now owns 56,671 shares of the medical research company’s stock valued at $10,461,000 after acquiring an additional 254 shares during the last quarter. Murphy Capital Management Inc. lifted its position in shares of Amgen by 2.3% during the 3rd quarter. Murphy Capital Management Inc. now owns 11,285 shares of the medical research company’s stock valued at $2,339,000 after acquiring an additional 254 shares during the last quarter. Fairfield Bush & CO. lifted its position in shares of Amgen by 0.8% during the 2nd quarter. Fairfield Bush & CO. now owns 33,934 shares of the medical research company’s stock valued at $6,264,000 after acquiring an additional 260 shares during the last quarter. Advisors Capital Management LLC lifted its position in shares of Amgen by 5.8% during the 2nd quarter. Advisors Capital Management LLC now owns 4,737 shares of the medical research company’s stock valued at $874,000 after acquiring an additional 261 shares during the last quarter. Finally, Mutual Advisors LLC lifted its position in shares of Amgen by 5.8% during the 2nd quarter. Mutual Advisors LLC now owns 4,814 shares of the medical research company’s stock valued at $889,000 after acquiring an additional 265 shares during the last quarter. 76.94% of the stock is owned by hedge funds and other institutional investors.

AMGN opened at $191.44 on Friday. The firm has a market capitalization of $126.81 billion, a PE ratio of 15.22, a price-to-earnings-growth ratio of 2.07 and a beta of 1.41. Amgen, Inc. has a 12-month low of $163.31 and a 12-month high of $210.19. The company has a quick ratio of 2.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.05.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.45 by $0.24. The company had revenue of $5.90 billion during the quarter, compared to analyst estimates of $5.78 billion. Amgen had a return on equity of 54.14% and a net margin of 9.44%. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.27 earnings per share. Sell-side analysts anticipate that Amgen, Inc. will post 14.24 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be issued a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.03%. This is a positive change from Amgen’s previous quarterly dividend of $1.32. Amgen’s dividend payout ratio is presently 41.97%.

In other news, SVP Cynthia M. Patton sold 1,777 shares of the stock in a transaction on Thursday, November 29th. The stock was sold at an average price of $202.88, for a total value of $360,517.76. Following the completion of the sale, the senior vice president now owns 23,090 shares in the company, valued at $4,684,499.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.19% of the stock is owned by corporate insiders.

A number of equities research analysts have recently commented on the company. Barclays reiterated a “neutral” rating and set a $195.00 price objective on shares of Amgen in a research report on Tuesday. BidaskClub upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 30th. Royal Bank of Canada reiterated a “neutral” rating and set a $182.00 price objective on shares of Amgen in a research report on Tuesday. Cantor Fitzgerald reiterated a “neutral” rating and set a $223.00 price objective on shares of Amgen in a research report on Tuesday. Finally, Morgan Stanley reiterated a “buy” rating and set a $213.00 price objective on shares of Amgen in a research report on Tuesday. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $205.68.

ILLEGAL ACTIVITY WARNING: This story was first posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.dailypolitical.com/2018/12/08/raymond-james-trust-n-a-raises-holdings-in-amgen-inc-amgn.html.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Further Reading: How can you know how many shares are floating?

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.